Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current. 

Category
done
done
done
Displaying 1 - 44 of 44
Date Sort ascending
CL_2021-44.pdf

INFORMATION ONLY
Blood Component and Special Request Order Form Updates

Customer Letter 2021-44 (PDF) | F040547 - Blood Component Order Form (PDF)100103465 - Special Request Order Form (PDF)

CL_2021-43.pdf

INFORMATION ONLY
J82 Insulator Biodegradable Change

Customer Letter 2021-43 (PDF) | 1) Biodegradable EPS Letter (PDF) | 2) Sustainable Insulation Evaluation Report (PDF)4) EPS Bio Sustainable Insulation Evaluation Report (PDF)5) Customer Letter 2015-24 (PDF)6) Customer Letter 2015-24 - Attachment 4 Term of Use (PDF)

CL_2021-42.pdf

INFORMATION ONLY
Anticoagulant Labelling Changes for Apheresis Products

Customer Letter 2021-42 (PDF)

CL_2021-41.pdf

INFORMATION ONLY
Results of the Request for Proposals (RFP) for Recombinant Plasma Protein and Related Products (PPRP)

Customer Letter 2021-41 (PDF)

CL_2021-40.pdf

INFORMATION ONLY
Revised date for the Introduction of Pathogen-Reduced Pooled Platelets in Ottawa

Ottawa site served hospitals only

Customer Letter 2021-40 (PDF)

CL_2021-39.pdf

ACTION REQUIRED
Revised Designated PPRP Request Form and Requesting Emicizumab for Expanded Criteria

Customer Letter 2021-39 (PDF) | FAQ for Updated Designated PPRP Request Form (PDF)

CL_2021-38.pdf

INFORMATION ONLY
Implementation Update: Introduction of ACD-A Apheresis Frozen Plasma

Customer Letter 2021-38 (PDF)

CL_2021-37.pdf

INFORMATION ONLY
Discontinuation of Apheresis Fresh Frozen Plasma 500mL

Customer Letter 2021-37 (PDF)

CL_2021-36.pdf

INFORMATION ONLY
Introduction of Additional Component Bags

Customer Letter 2021-36 (PDF)

CL_2021-35.pdf

INFORMATION and ACTION REQUIRED
Blood and Blood Product Deliveries: Potential Impact of Hospital Mandatory Vaccination Policies

Customer Letter 2021-35 (PDF)

CL_2021-34.pdf

INFORMATION ONLY
Emicizumab (Hemlibra®) for severe hemophilia A without FVIII inhibitors

Customer Letter 2021-34 (PDF)

CL_2021-33.pdf

INFORMATION FOR ALBERTA HOSPITAL CUSTOMERS ONLY
Transfer of Red Cell (HEA and RHCE) Genotype Testing

Customer Letter 2021-33 (PDF)

CL_2021-32.pdf

INFORMATION ONLY
ADYNOVATE® Updates

Customer Letter 2021-32 (PDF) | ADYNOVATE Customer Letter (PDF)

CL_2021-31.pdf

INFORMATION ONLY
Introducing Pathogen-Reduced Pooled Platelets in Ottawa

Customer Letter 2021-31 (PDF)

CL_2021-30.pdf

INFORMATION ONLY
Revision of Request for Serological Investigation Form

Customer Letter 2021-30 (PDF) | Request for Serological Investigation (PDF)

CL_2021-29.pdf

INFORMATION ONLY
Fibrinogen concentrate – no restrictions on brand mix

Customer Letter 2021-29 (PDF)

CL_2021-28.pdf

ACTION REQUIRED
Introducing pathogen-reduced Pooled Platelets and associated new ISBT Component Codes
Ottawa site served hospitals only

Customer Letter 2021-28 (PDF)

CL_2021-27.pdf

ACTION REQUIRED
Recall Notification Distribution

Customer Letter 2021-27 (PDF) | NCRW Example (JPG)

CL_2021-26.pdf

ACTION REQUIRED
Introduction of ACD-A Apheresis Frozen Plasma

Customer Letter 2021-26 (PDF)

CL_2021-25.pdf

INFORMATION ONLY
Hizentra® 20% Liquid 20 mL (4g) Pre-filled Syringe Availability

Customer Letter 2021-25 (PDF) | Hizentra® Prefilled Syringe (PDF) | Hizentra® Fact Sheet (PDF)

CL_2021-24.pdf

INFORMATION ONLY
Special Request Order Form

Customer Letter 2021-24 (PDF)

CL_2021-23.pdf

INFORMATION ONLY
Albumin 5% 500 mL Availability

Customer Letter 2021-23 (PDF) | Albumin 5% Introduction Letter (PDF) | Product Profile Albumin (PDF)

CL_2021-22.pdf

INFORMATION ONLY
Bacterial Test Result Notification to Hospitals – New Form

Customer Letter 2021-22 (PDF) | Bacterial Testing Results Notification (PDF)

CL_2021-21.pdf

INFORMATION ONLY
Introduction of Fibryga® Kit - Now Co-Packaged with Water for Injection

Customer Letter 2021-21 (PDF) | Fibryga Kit with WFI CBS HCP Customer Letter (PDF)

CL_2021-20.pdf

INFORMATION ONLY
Updated Share Splits for Intravenous Immunoglobulins

Customer Letter 2021-20 (PDF)

CL_2021-19.pdf

INFORMATION ONLY
RiaSTAP® Reconstitution Devices “Spike and Syringe Filter” available in RiaSTAP® package

Customer Letter 2021-19 (PDF) | RiaSTAP® Reconstitution Devices “Spike and Syringe Filter” now available in RiaSTAP® package (PDF)

CL_2021-18.pdf

INFORMATION ONLY
Introduction of HAEGARDA®

Customer Letter 2021-18 (PDF) | Product Profile Template HAEGARDA® (PDF) | HAEGARDA vendor letter (PDF)

CL_2021-17.pdf

INFORMATION ONLY
Intravenous Immunoglobulin (IVIg) Brand Switching Guidance and Resources from The National Advisory Committee on Blood and Blood Products (NAC)

Customer Letter 2021-17 (PDF) | Intravenous Immunoglobulin (IVIg) Brand Switching (PDF)

CL_2021-16.pdf

INFORMATION ONLY
Follow-up of Canadian Blood Services Platelet Bacterial Testing Results

Customer Letter 2021-16 (PDF) | Follow-up of Canadian Blood Services Platelet Bacterial Testing Results (PDF)

CL_2021-15.pdf

INFORMATION ONLY
Updates regarding Hemlibra® (emicizumab injection)

Customer Letter 2021-15 (PDF) | Drug Product Shelf Life Reduction (PDF) | Introduction of Transfer Needle with Filter (PDF)

CL_2021-14.pdf

INFORMATION ONLY
Octagam® 10% Availability

Customer Letter 2021-14 (PDF) | Product Profile Octagam (PDF) | Octagam Availability Customer Letter (PDF)

CL_2021-13.pdf

INFORMATION ONLY
New CSL Behring Contact Number for Urgent Inquiries and Afterhours Service

Customer Letter 2021-13 (PDF) | CSL Behring Contact Number (PDF)

CL 2021-12.pdf

INFORMATION ONLY
WinRho® SDF Labelling – Repackaged WinRho® SDF 1000 mcg (5000 IU) Lot 230029571

Customer Letter 2021-12 (PDF) | Customer notification repackaging activity for WinRho® (PDF)

CL_2021-11.pdf

INFORMATION ONLY
Updates to Solvent Detergent Plasma - Request Form

Customer Letter 2021-11 (PDF) | Solvent Detergent Plasma - Request Form

CL 2021-10.pdf

ACTION REQUIRED
Hospital Monitoring of Ig Supply

Customer Letter 2021-10 (PDF) 

CL 2021-09.pdf

INFORMATION ONLY
Introduction of X-ray Irradiation

Customer Letter 2021-09 (PDF) 

CL_2021-08.pdf

ACTION REQUIRED
Immunoglobulin (Ig) Inventory Update and Reminder of Action for Hospitals

Customer Letter 2021-08 (PDF) | National Emergency Blood Management Committee Letter (PDF)

CL_2021-07.pdf

INFORMATION ONLY
Updates to the Blood Component and Special Request Order Forms

Customer Letter 2021-07 (PDF) | Blood Component Order Form (PDF) | Special Request Order Form (PDF)

CL_2021-06.pdf

INFORMATION ONLY
Update to J82 and E38 Shipping Containers for Inter-Hospital Transfers

Customer Letter 2021-06 (PDF)

CL_2021-05.pdf

INFORMATION ONLY
Release of Revised Circular of Information for Red Blood Cells, Platelets, and Plasma

Customer Letter 2021-05 (PDF)

CL_2021-04.pdf

INFORMATION ONLY
WinRho® SDF Labelling

Customer Letter 2021-04 (PDF) | Saol Customer Notification

CL_2021-03.pdf

INFORMATION ONLY
Privigen® Inventory

Customer Letter 2021-03 (PDF)

CL_2021-02.pdf

INFORMATION ONLY
Update on Panhematin® Packing Supply

Customer Letter 2021-02 (PDF)

CL_2021-01.pdf

INFORMATION ONLY
Revision to Transfusion Related Acute Lung Injury (TRALI) Patient Data Form

Customer Letter 2021-01 (PDF)